CN102186994A - 诊断或预后上皮性卵巢癌的方法 - Google Patents

诊断或预后上皮性卵巢癌的方法 Download PDF

Info

Publication number
CN102186994A
CN102186994A CN2009801412434A CN200980141243A CN102186994A CN 102186994 A CN102186994 A CN 102186994A CN 2009801412434 A CN2009801412434 A CN 2009801412434A CN 200980141243 A CN200980141243 A CN 200980141243A CN 102186994 A CN102186994 A CN 102186994A
Authority
CN
China
Prior art keywords
eoc
binding moiety
sox11
ovarian cancer
epithelial ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801412434A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·K·博雷贝克
S·C·A·埃克
D·J·布伦南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovia AB
Original Assignee
Immunovia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia AB filed Critical Immunovia AB
Publication of CN102186994A publication Critical patent/CN102186994A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2009801412434A 2008-09-01 2009-09-01 诊断或预后上皮性卵巢癌的方法 Pending CN102186994A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0815846.1 2008-09-01
GBGB0815846.1A GB0815846D0 (en) 2008-09-01 2008-09-01 diagnosis, prognosis and imaging of disease
PCT/GB2009/002098 WO2010023458A1 (en) 2008-09-01 2009-09-01 Method of diagnosing or prognosing epithelial ovarian cancer

Publications (1)

Publication Number Publication Date
CN102186994A true CN102186994A (zh) 2011-09-14

Family

ID=39866018

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801412434A Pending CN102186994A (zh) 2008-09-01 2009-09-01 诊断或预后上皮性卵巢癌的方法

Country Status (7)

Country Link
US (4) US20110217238A1 (enExample)
EP (1) EP2329042B1 (enExample)
JP (1) JP2012501318A (enExample)
CN (1) CN102186994A (enExample)
ES (1) ES2605254T3 (enExample)
GB (1) GB0815846D0 (enExample)
WO (1) WO2010023458A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105917230A (zh) * 2013-11-11 2016-08-31 伊缪诺维亚公司 用于确定胰腺癌的方法、阵列和其用途
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
GB0910620D0 (en) * 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
AU2012283869B2 (en) 2011-07-20 2017-06-15 Mikroscan Technologies, Inc. Network-based pathology system with desktop slide scanner
WO2013176958A1 (en) * 2012-05-21 2013-11-28 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
AU2014348371B2 (en) 2013-11-15 2019-11-07 Mikroscan Technologies, Inc. Geological scanner
WO2016069794A1 (en) 2014-10-28 2016-05-06 Mikroscan Technologies, Inc. Microdissection viewing system
US20170097355A1 (en) * 2015-10-06 2017-04-06 University Of Washington Biomarkers and methods to distinguish ovarian cancer from benign tumors
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy
AU2004256182A1 (en) * 2003-07-02 2005-01-20 Novartis Ag Genes regulated in ovarian cancer as prognostic and therapeutic targets
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105917230A (zh) * 2013-11-11 2016-08-31 伊缪诺维亚公司 用于确定胰腺癌的方法、阵列和其用途
CN105917230B (zh) * 2013-11-11 2020-06-16 伊缪诺维亚公司 用于确定胰腺癌的方法、阵列和其用途
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途

Also Published As

Publication number Publication date
ES2605254T3 (es) 2017-03-13
EP2329042A1 (en) 2011-06-08
US20220390452A1 (en) 2022-12-08
GB0815846D0 (en) 2008-10-08
EP2329042B1 (en) 2016-10-26
US20190018016A1 (en) 2019-01-17
US20160047815A1 (en) 2016-02-18
WO2010023458A1 (en) 2010-03-04
JP2012501318A (ja) 2012-01-19
US20110217238A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
US20220390452A1 (en) Method of diagnosing or prognosing epithelial ovarian cancer
AU2005289728B2 (en) Methods and compositions for evaluating breast cancer prognosis
Rosa Advances in the molecular analysis of breast cancer: pathway toward personalized medicine
CN116113712A (zh) 用于癌症的预后生物标志物
Wang et al. Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma
Kohsaka et al. Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling
US9388469B2 (en) Sox11 expression in malignant lymphomas
Cheung et al. Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping
CN113846164A (zh) 用于预测患者对术前放化疗联合全直肠系膜切除术敏感性的标志分子及其衍生产品
CN113817825A (zh) 预测直肠癌患者对术前放化疗联合全直肠系膜切除术治疗敏感性的分子标志物
Amer et al. DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer
JP7453284B2 (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
US20060134622A1 (en) Amplified cancer target genes useful in diagnosis and thereapeutic screening
Wang et al. ERBB‐2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas
Cao et al. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer
US20230133776A1 (en) Methods for diagnosing cancer
CN113862356A (zh) 通过标志物预测直肠癌对术前放化疗联合全直肠系膜切除术治疗方案敏感性的产品
CN113862357A (zh) 基于生物标志物预测直肠癌对术前放化疗联合全直肠系膜切除术敏感性的产品及其用途
EP2269073B1 (en) A method of assessing cancer status in a breast cancer patient
Pervez et al. Predictive pathology
Lee et al. Improved prognostic stratification with 2023 FIGO staging in endometrial cancer reflecting poor prognosis of aggressive histological types and p53 abnormality
US9784743B2 (en) Collagens as markers for breast cancer treatment
CN119269806A (zh) Ciapin1在胶质瘤的诊断或预后中的应用及相关的计算机可读介质
JP2022032795A (ja) 子宮内膜癌の発症の予測方法
de Lartigue Delivering on the promise of cancer biomarkers in the clinic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110914